Skip to content

Effects of Hookah Smoking on Blood Flow to the Heart, Muscle and Skin

Effects of Hookah Smoking on Blood Flow to the Heart, Muscle and Skin

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02147665
Enrollment
42
Registered
2014-05-28
Start date
2013-03-31
Completion date
2016-03-31
Last updated
2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hookah Smoking

Keywords

Hookah, waterpipe, smoking, sympathetic

Brief summary

This is a pilot study on acute effects of Hookah smoking on the sympathetic neural control of the human cardiovascular system. Hookah smoking is known to transiently increase blood pressure and heart rate while decreasing heart rate variability suggesting - but not proving - sympathetic mediation. Here the investigators will directly measure the acute effects of Hookah smoking on sympathetic nerve activity with microneurography (intraneural microelectrodes) and quantify associated regional changes in vasomotor tone.

Interventions

Subjects will smoke waterpipe in a controlled research environment.

Sponsors

Cedars-Sinai Medical Center
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 39 Years
Healthy volunteers
Yes

Inclusion criteria

* 18 to 39 years of age * Habitual Hookah smoker defined as having smoked Hookah \>=12 times in the past 12 months * Have not smoked cigarettes within the past 12 months

Exclusion criteria

* Exhaled carbon monoxide level greater than 10 ppm\* as evidence of current or recent cigarette (excluded if smoked cigarette within 12 months) or Hookah smoking (excluded if smoked Hookah within past 72 hours) * History of cardiopulmonary disease * Use of any prescription medication with exception of oral contraceptive pills * History of psychiatric illness * History of neurologic disease * BMI ≥ 35 * Evidence of any of the above by physical examination, ECG or echocardiogram * Smoked cigarette in the past 12 months * History of illicit drug use * Pregnant * Any other condition(s) deemed by the physician investigators that put subjects at risk for participating in the study

Design outcomes

Primary

MeasureTime frameDescription
Sympathetic nerve activityAt the initial study visitMulti-unit recordings of sympathetic nerve activity will be obtained with single-use sterile tungsten microelectrodes inserted selectively into muscle or skin nerve fascicles of the peritoneal nerve.

Secondary

MeasureTime frameDescription
Myocardial contrast echocardiographyAt the initial study visitMyocardial contrast echocardiography will be used to measure regional myocardial perfusion (i.e. capillary blood volume) and coronary flow reserve.

Other

MeasureTime frameDescription
Venous Occlusion PlethysmographyAt the initial study visitLower leg blood flow will be measured with standard venous occlusion plethysmography.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026